A subset of low density granulocytes is associated with vascular calcification in chronic kidney disease patients
A subset of low density granulocytes is associated with vascular calcification in chronic kidney disease patients
Bisphosphonate treatment changes regional distribution of trabecula microstructure in human lumbar vertebrae
2019 Jul 4;127:482-487. doi: 10.1016/j.bone.2019.07.003 PubMed PMID: 31280018. Vom Scheidt A, Hemmatian H, Püschel K, Krause M, Amling M, Busse B. Bone.
Increased risk of osteoporotic fracture in community-dwelling elderly men 20 or more years after gastrectomy: The Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study
2019 Jun 26;127:250-259. doi: 10.1016/j.bone.2019.06.014 PubMed PMID: 31254731 Iki M, Fujita Y, Kouda K, Yura A, Tachiki T, Tamaki J, Sato Y, Moon JS, Hamada M, Kajita E, Okamoto N, Kurumatani N Bone.
Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
2019 Jun 24. doi: 10.1002/jbmr.3735. PMID: 31233639 Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A J Bone Miner Res. Más información: https://www.ncbi.nlm.nih.gov/pubmed/31233639
Low vitamin D status is associated with impaired bone quality and increased risk of fracture-related hospitalization in older Australian women.
Res. 2019 Jun 24. doi: 10.1002/jbmr.3818 PMID: 31233633 Zhu K, Lewis JR, Sim M, Prince RL J Bone Miner Más información: https://www.ncbi.nlm.nih.gov/pubmed/31233633
Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta
2019 Jun 16;127:164-171. doi: 10.1016/j.bone.2019.06.011 PMID: 31216496 Li LJ, Zheng WB, Zhao DC, Yu W, Wang O, Jiang Y, Xia WB, Li M Bone. Más información: https://www.ncbi.nlm.nih.gov/pubmed/31216496
Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom
Osteoporos Int. 2019 Jul 3. doi: 10.1007/s00198-019-05064-w Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R, Stollenwerk B. https://www.ncbi.nlm.nih.gov/pubmed/31270592
Epidemiology/Quality of Life Working Group. Fracture risk following intermission of osteoporosis therapy
Osteoporos Int. 2019 Jun 7. doi: 10.1007/s00198-019-05002-w Dennison EM, Cooper C, Kanis JA, Bruyère O, Silverman S, McCloskey E,Abrahamsen B, Prieto-Alhambra D, Ferrari S; IOF https://www.ncbi.nlm.nih.gov/pubmed/31175404
Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone
J Bone Miner Res. 2019 Apr;34(4):653-660. doi: 10.1002/jbmr.3649 Florenzano P, Pan KS, Brown SM, Paul SM, Kushner H, Guthrie LC, de Castro LF, Collins MT, Boyce AM. https://www.ncbi.nlm.nih.gov/pubmed/30645769
The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment
Endocrine. 2019 Jun;64(3):441-455. doi: 10.1007/s12020-019-01919- Guañabens N, Moro-Álvarez MJ, Casado E, Blanch-Rubió J, Gómez-Alonso C, Díaz-Guerra GM, Del Pino-Montes J, Díaz de Lamadrid CV, Peris P, Muñoz-Torres M; SEIOMM Working Group https://www.ncbi.nlm.nih.gov/pubmed/30963388
